Laila Poisson

This study identifies genetic changes in IDH-mutant gliomas that correlate with treatment response and tumor evolution using longitudinal genomic data from 206 patient samples.

This study examines how genomic background and developmental state affect signaling pathways and therapy response in GBM patient-derived cells, finding that differentiation increases TMZ resistance and activates DNA-damage interferon responses.

This study uses untargeted metabolomics to identify altered serum metabolites distinguishing relapsing-remitting MS, progressive MS, and healthy subjects.

The paper identifies altered omega fatty acid-derived lipid mediators in RRMS patients using metabolipidomics, suggesting their potential as biomarkers for diagnosis and prognosis.

This study analyzes the epigenetic evolution of IDH1-mutant and IDH1-wildtype gliomas under treatment, showing IDHmut tumors undergo epigenomic changes resembling IDHwt tumors, with implications for treatment strategies.

This study uses iPSC-derived astrocytes to compare metabolic and inflammatory responses between AMN and cALD phenotypes in X-ALD, identifying miR-9 as associated with disease severity.

The paper identifies altered metabolic pathways in RRMS patients using metabolomics and shows that targeting glycolysis can reduce disease progression in a mouse model.

The paper identifies an epigenetic shift from G-CIMP-high to G-CIMP-low in gliomas during recurrence, associated with genomic instability and stem cell-like features, and proposes biomarkers for predicting recurrence.